Consensus Perspective Therapeutics, Inc.

Stocks

CATX

US46489V3024

Biotechnology & Medical Research

Real-time Estimate Cboe BZX Other stock markets 10:00:26 2026-06-18 am EDT			5-day change	1st Jan Change
3.080 ^USD	+3.36%		+1.85%	+10.00%

Jun. 03	Perspective Therapeutics Doses First Meningioma Patient in Phase 1/2a Study Cohort	MT
Jun. 03	Perspective Therapeutics Doses First Patient with [212Pb]Vmt-?-Net in Meningioma Cohort of Phase 1/2A Study	CI

Evolution of the Average Target: Perspective Therapeutics, Inc.

Evolution of the Target Price: Perspective Therapeutics, Inc.

Changes in Analyst Recommendations: Perspective Therapeutics, Inc.

4f.4SKH4DA6Lq535YBdz3EV0b0APn_x1GO7GKliSVtzkTo.plbI13FlR-go3NU7tRY4gs85Ug20s1vPYMIhHgQS1Fa5bbeUeUIazwG_sA~0173067d71c8fa0fdaf56adefd67c254

Analysts' recommendations: Perspective Therapeutics, Inc.

Mar. 18	UBS Adjusts Price Target on Perspective Therapeutics to $8 From $7, Maintains Buy Rating	MT
Mar. 18	B. Riley Raises Price Target on Perspective Therapeutics to $13 From $11, Keeps Buy Rating	MT
Mar. 17	RBC Cuts Price Target on Perspective Therapeutics to $14 From $18, Keeps Outperform, Speculative Risk	MT
Feb. 19	Piper Sandler Initiates Coverage on Perspective Therapeutics With Overweight Rating	MT
Nov. 18	B. Riley Adjusts Price Target on Perspective Therapeutics to $11 From $12, Maintains Buy Rating	MT
25-10-10	BTIG Research Initiates Coverage on Perspective Therapeutics With Buy Rating, $14 Price Target	MT
25-06-23	B. Riley Raises Price Target on Perspective Therapeutics to $12 From $9, Keeps Buy Rating	MT
25-06-03	RBC Raises Price Target on Perspective Therapeutics to $16 From $15, Keeps Outperform, Speculative Risk	MT
25-05-14	Truist Securities Adjusts Perspective Therapeutics Price Target to $8 From $10, Maintains Buy Rating	MT
25-05-13	Oppenheimer Trims Perspective Therapeutics Price Target to $15 From $16, Maintains Outperform Rating	MT
25-04-07	Truist Securities Adjusts Price Target on Perspective Therapeutics to $10 From $21, Keeps Buy Rating	MT
25-03-27	RBC Cuts Price Target on Perspective Therapeutics to $15 From $16, Keeps Outperform, Speculative Risk	MT
25-03-13	HC Wainwright Initiates Coverage on Perspective Therapeutics With Buy Rating, $10 Price Target	MT
25-03-10	Brookline Initiates Perspective Therapeutics at Buy With $11 Price Target	MT
24-11-26	B. Riley Securities Adjusts Price Target on Perspective Therapeutics to $9 From $17, Keeps Buy Rating	MT
24-11-25	BofA Securities Downgrades Perspective Therapeutics to Neutral From Buy, Price Target is $6	MT
24-11-25	RBC Cuts Price Target on Perspective Therapeutics to $16 From $25, Keeps Outperform, Speculative Risk	MT
24-11-13	RBC Trims Price Target on Perspective Therapeutics to $25 From $27, Keeps Outperform, Speculative Risk	MT
24-10-24	UBS Initiates Perspective Therapeutics at Buy With $20 Price Target	MT
24-10-11	Top Midday Decliners	MT
24-10-11	Wedbush Adjusts Price Target on Perspective Therapeutics to $20 From $25, Maintains Outperform Rating	MT
24-10-01	Wedbush Initiates Perspective Therapeutics at Outperform With $25 Price Target	MT
24-09-25	Truist Initiates Perspective Therapeutics at Buy With $21 Price Target	MT
24-09-25	Truist Initiates Perspective Therapeutics at Buy	MT
24-08-16	RBC Adjusts Perspective Therapeutics' PT to $27 From $29, Keeps Outperform Rating, Speculative Risk	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	PERSPECTIVE THERAPEUTICS, INC.					+334%
	LONZA GROUP AG					+34.51%
	REVOLUTION MEDICINES, INC.					+18.71%
	IQVIA HOLDINGS INC.					+32.2%
	BEONE MEDICINES AG					+56.98%
	CELLTRION, INC.					+45.19%
	MEDPACE HOLDINGS, INC.					-3.12%
	EUROFINS SCIENTIFIC SE					+13.34%
	IONIS PHARMACEUTICALS, INC.					+40.71%
	Average					+63.61%
	Weighted average by Cap.					+33.25%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.980USD

Average target price

12.93USD

Spread / Average Target

+334.00%

High Price Target

18.00USD

Spread / Highest target

+504.03%

Low Price Target

6.000USD

Spread / Lowest Target

+101.34%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

UBS
B. Riley
RBC Capital Markets
Piper Sandler
BTIG
Truist Securities
Oppenheimer
HC Wainwright
Brookline Capital Markets
BofA Securities
Wedbush
Cantor Fitzgerald
JonesTrading Institutional Services
Northland Securities